BioSpace News Archive

Noxopharm (ASX: NOX) is pleased to announce positive interim results from its LuPIN Phase 1/2 clinical trial. The data was presented during a poster presentation at the ASCO Genitourinary Cancers (GU) Symposium 2020 in San Francisco by St. Vincent’s Hospital Sydney.

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the Company will release fourth quarter and full year 2019 financial results on Monday, February 24, 2020 after the close of market.

EMERYVILLE, Calif. , Feb. 14, 2020 /PRNewswire/ -- Biossance, a pioneering clean skincare brand from Amyris, Inc. (NASDAQ: AMRS), a global science and technology leader of pure, sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, is thrilled to announce The Clean Academy, the brand’s award-winning educational platform, is b

Caretaker Medical, a leader in clinical-grade wireless patient monitoring and maker of the Caretaker® wearable patient monitor that utilizes a simple Finger Cuff to measure Real-time “Beat by Beat” Continuous Blood Pressure, Respiration Rate, and other hemodynamic parameters, has incorporated VivaLNK’s FDA-Cleared ECG Patch to their wireless patient monitoring platform.

WAT Medical is thrilled to announce the newest clinical study conducted for an anti-migraine device by the HeadaTerm, for the treatment of migraines

Taconic Biosciences, a global leader in providing drug discovery animal model solutions, announces its humanized immune system mice models are now being produced in Europe.

ARMA Sport Inc. (“ARMA”), an action and adventure lifestyle-driven brand founded by action sports industry veterans from Oakley, Spy, Dragon, and Monster Energy, with seven-time AMA Supercross Champion and motocross legend Jeremy McGrath, proudly announces the launch of its sports nutrition performance and recovery products.

HOPKINTON, Mass., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Spring Bank Pharmaceuticals, Inc. (Nasdaq: SBPH), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of certain cancers and inflammatory diseases, today announced its financial results for the fourth quarter and year-ended December 31, 2019 and provided an update on recent corporate and clinical development highlights. “In January, we made the difficult decision to discontinue our development efforts

Premier orthopedic practice will add 27 new providers to Banner’s employed medical group

The contours of the active pharmaceutical ingredients (API) market have been notably shaped by the evolving regulatory and compliance landscape